Two months after the last chemotherapy, Bianca Balti resumes her battle against cancer. Fresh from participating in the Milan ...

NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...

AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE� (mirvetuximab soravtansine-gynx) in women with folate ...

AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer. The drug has gone on to become a huge success ...

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

NASA’s Perseverance rover has found possible hints of ancient life on Mars ― one of the strongest signs yet of Martian life, according to planetary scientists. Dark-rimmed ‘leopard spots ...

TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

The team found evidence of a major meteorite impact 3.5 billion ... Giant Ice Bulldozers: How Ancient Glaciers Helped Life Evolve Feb. 25, 2025 — New research has revealed how massive ancient ...

NEW YORK, February 13, 2025--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP ...

The new data from the DUO-E study found that PD-L1 inhibitor Imfinzi (durvalumab) and PARP inhibitor Lynparza (olaparib) – as well as Imfinzi alone – extended the time to disease progression ...

Mar. 12, 2025 — A critically endangered new species of killifish sampled from an ancient forest in Kenya in 2017 and 2018 has now been described. Nothobranchius sylvaticus, from the Latin ...

Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...